The patient, who’s being treated at the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, Mo., was implanted with the InVivo device about 10 hours after a traumatic spinal injury, the Cambridge, Mass.-based company said.
“We were able to get the patient into the operating room in such an expeditious manner, thanks to the experienced trauma and neurosurgical teams at the Barnes-Jewish Hospital,” said Dr. Wilson “Zack” Ray, a member of the Inspire study’s steering committee, in prepared remarks. “The implantation procedure was straightforward and the patient is recovering well. I look forward to following the patient’s progress.”
“Once again, it has been demonstrated that neuro-spinal scaffold implantation is readily performed within 12 hours post-injury, which is earlier than most standard of care spine stabilization surgery. We look forward to diligently monitoring this patient’s outcomes and enrolling additional patients into this landmark study,” InVivo chairman & CEO Mark Perrin said.
NVIV shares were up 5.1% to $4.96 apiece today in mid-morning trading.
Last month, InVivo Therapeutics said it won FDA approval to shift the Inspire pilot trial of its spinal scaffold to a pivotal probable benefit study. Earlier this month, the company added the University of California’s San Diego Medical Center as a site for the Inspire trial.